Navigation Links
Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger

SAN DIEGO and MIAMI, Sept. 18 /PRNewswire-FirstCall/ -- Sorrento Therapeutics, Inc. ("STI"), a privately-held and development-stage biopharmaceutical company with a proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, has merged with a wholly-owned subsidiary of QuikByte Software, Inc. (OTC Bulletin Board: QBSW), a publicly-traded company with no active operations. As a result of the merger, Sorrento has become a wholly-owned subsidiary of QuikByte. In connection with the consummation of the merger, QuikByte intends to change its name to "Sorrento Therapeutics, Inc." and redomesticate to a corporation incorporated under the laws of the State of Delaware. The combined company will be headquartered in San Diego, California.

Immediately prior to the closing of the merger, QuikByte completed a $2 million private placement of its common stock to certain investors, including affiliates of Dr. Phillip Frost, Chairman and Chief Executive Officer of OPKO Health, Inc. (NYSE Amex: OPK), which was a stockholder of STI prior to the merger, and an affiliate of Mr. Glenn L. Halpryn, a director of QuikByte and its Chairman, President and Chief Executive Officer prior to the merger, and Mr. Steven Jerry Glauser, a greater than 5% shareholder of QuikByte, President of the Glauser Group, Denver, Colorado and President and Managing Partner of Alex Rodriguez Mercedes Benz, Houston, Texas.

Upon the completion of the merger, after giving effect to the private placement, the QuikByte shareholders as of immediately prior to the private placement owned approximately 4.92% of the combined company, the investors in the private placement, some of whom were QuikByte or STI shareholders prior to the private placement, owned approximately 19.83% of the combined company, not including the shares of QuikByte which they owned prior to the private placement or which were issued to them in connection with the merger, and the former STI stockholders (including OPKO) owned approximately 75.25% of the combined company, in each case on a fully-diluted basis.

In connection with the merger, Dr. Antonius Schuh, who was the Chief Executive Officer of STI immediately prior to the merger, was appointed Chief Executive Officer of QuikByte, and Dr. Henry Ji, the inventor of the STI technology, who was the Chief Scientific Officer of STI prior to the merger, was appointed Chief Scientific Officer of QuikByte. Upon the merger, the board of directors of QuikByte was reconstituted to include four directors appointed by Dr. Schuh, who include Drs. Schuh and Ji, two directors appointed by OPKO and one director appointed by QuikByte.

Dr. Schuh commented, "Sorrento Therapeutics is excited to join with QuikByte, OPKO and Dr. Frost as we develop our proprietary platform technology for the generation of fully human monoclonal antibodies."

Mr. Glenn L. Halpryn, the Chairman, President and Chief Executive Officer of QuikByte prior to the merger stated, "We are pleased that QuikByte has this opportunity to enter into the growing field of human antibodies with an experienced team led by Drs. Schuh and Ji. The merger provides QuikByte shareholders with the opportunity to benefit from the experience of Sorrento's management and its proprietary technology as the Company develops its human antibody library." Mr. Halpryn will remain a director of QuikByte following the merger.

The securities issued in the private placement have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration under the Securities Act of 1933 and applicable state securities laws or available exemptions from registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

About Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc., a wholly-owned subsidiary of QuikByte Software, Inc., is a development-stage biopharmaceutical company focused on applying its proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic disease and infectious disease. The Company seeks to construct an antibody library containing fully human antibodies and designed to facilitate the rapid identification and isolation of highly specific, antibody therapeutic product candidates that are fully human and that bind to disease targets appropriate for antibody therapy.

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects, the merger and the other transactions contemplated by the merger agreement. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to, the possibility that some or all of the pending matters and transactions considered by QuikByte may not proceed as contemplated, and by all other matters specified in QuikByte's filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and product candidates. These statements are made based upon current expectations that are subject to risk and uncertainty and information available to QuikByte as of the date of this press release. QuikByte does not undertake to update forward-looking statements in this press release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in QuikByte's filings with the Securities and Exchange Commission, including its most recent periodic report. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

SOURCE Sorrento Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
2. Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)
3. Cell Therapeutics, Inc. (CTI) to Present at BioCenturys NewsMakers in the Biotech Industry Conference
4. Oxygen Biotherapeutics, Inc. Seeks Shareholder Approval for Reverse Stock Split
5. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw Healthcare Conference
6. Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich
7. Cell Therapeutics, Inc. Announces Closing of Registered Offering of $30 Million of Preferred Stock and Warrants
8. Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants
9. Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009
10. Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
11. Cell Therapeutics, Inc. Announces Exercise of Overallotment
Post Your Comments:
(Date:10/8/2015)... Celemics, a global pioneer of personalized medicine ... market with the establishment of Celemics America, Inc. ... Europe , has secured itself in the global ... sample preparation for DNA sequencing and genetic testing.  Next ... genetic testing more accurately, quickly, and cost effectively than ...
(Date:10/8/2015)... 8, 2015  The ALS Association, in partnership with ... Challenge to revolutionize communication technology solutions for people living ... ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative ... and the spinal cord. Eventually, people with ALS lose ... often leads to total paralysis and death within two ...
(Date:10/8/2015)... ... October 08, 2015 , ... ProMIS ... license agreement to develop and commercialize intellectual property rights belonging to The University ... February 2009, and affords exclusive worldwide rights to intellectual property based on use ...
(Date:10/7/2015)... Dallas-Fort Worth, Texas (PRWEB) , ... October 07, ... ... Stem Cell Institute ( ) will present a public educational seminar on ... diseases on Saturday, October 10th from 1:00 pm – 3:00 pm at the ...
Breaking Biology Technology:
... Sciences, Inc. (Nasdaq: CALP ) today announced that ... "Innovation for Experimentation" to be held June 17, 2009 at ... Breakout Session from 2:30 - 4:00 p.m. EDT. , ... by Kevin Hrusovsky, President and CEO, as well as several ...
... BEIJING, June 8 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE ... in China, announced today that it,begins the production of a vaccine ... CDC and was delivered to the company on June 8, 2009. ... CEO of Sinovac, commented, ,In,the midst of a global outbreak and ...
... to Help Ease Venipuncture Process , , UnitedPharma ... , COLD SPRING HARBOR, N.Y., June 8 ... Services for America,s Blood Centers (GSABC) bringing the AccuVein ... to GSABC member blood centers. Under the agreement, ...
Cached Biology Technology:
(Date:9/10/2015)... , Sept. 10, 2015 This report ... wearable technology products today, and emerging sensor types that ... risen through the peak of the wearable technology hype ... slide to disillusionment. The common feature with all of ... key enabler for their most useful functions. Sensors collect ...
(Date:9/10/2015)... Sept. 10, 2015 Report Details ... quite delivered upon previous expectations of revenues, consumer adoption ... breakthrough year in which wearables begin to achieve that ... of the main reasons is the entrance of Apple ... the SmartWatches market, but the overall size of the ...
(Date:9/10/2015)... 10, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that the ... Touch of Modern, will feature the Wocket® smart wallet ... . Touch Of Modern is ... lifestyle products to its 7.2 million members. Customers are ...
Breaking Biology News(10 mins):
... massive changes to the Earth's landscape , The ice ages ... happening below the ice in the oceans? , Research by ... destruction as whole communities of animals were wiped out by ... it has been thought that these ecosystems somehow dodged extinction ...
... at the Naval Research Laboratory's Marine Meteorology Division ... Monterey Bay Aquarium Research Institute and the National ... of a phenomenon known as the "milky sea." ... ship-based account. This research was published in the ...
... Wright Brothers' first biplanes to monoplanes was an inadvertent ... say two dino flight experts. , According to ... a small early Chinese dinosaur called Microraptor gui used ... to tree in the early Cretaceous. Among the evidence ...
Cached Biology News: